Solara Active Pharma Sciences confirms no deviation in utilization of ₹309.79 crore Rights Issue proceeds as of March 31, 2026.
Audit Committee reviewed and approved the utilization statement without comments at its May 15, 2026 meeting.
Funds were utilized for debt repayment (₹233.61 crore) and general corporate purposes (₹74.97 crore) as per original objects.
First call money of ₹155.31 crore was received, with ₹154.10 crore utilized and ₹1.21 crore pending utilization in monitoring accounts.